Cheng H M, Foong Y T, Mathew A, Sam C K, Dillner J, Prasad U
Nasopharyngeal Carcinoma Research Laboratory, University Malaya, Kuala Lumpur, Malaysia.
J Virol Methods. 1993 Apr;42(1):45-51. doi: 10.1016/0166-0934(93)90175-q.
An ELISA using the Epstein-Barr virus nuclear antigen 1 (EBNA 1) was found to detect selectively specific IgA in sera from patients with nasopharyngeal carcinoma (NPC). The antigen, p107, was a 20-amino acid synthetic peptide, representing a major epitope of EBNA 1.267/294 (90.8%) of NPC patients had IgA antibodies to p107 but in normal individuals, only 41/577 (7.1%) had IgA/p107. In sera from patients with other cancers, 11/77 (14.3%) had IgA/p107 reactivity. 124 IgA/VCA positive and 86 IgA/VCA negative NPC sera were also tested for IgA/p107 binding in ELISA. The majority of IgA/VCA positive sera (117) also contained IgA/p107 antibodies. Of interest was the detection of 74/86 IgA/p107 reactive sera in the IgA/VCA negative group. The results suggest that the IgA/p107 ELISA could become a useful, complementary screening assay to the IgA/VCA immunofluorescence test for detection of NPC.
一种利用爱泼斯坦-巴尔病毒核抗原1（EBNA 1）的酶联免疫吸附测定（ELISA）被发现可选择性地检测鼻咽癌（NPC）患者血清中的特异性IgA。抗原p107是一种20个氨基酸的合成肽，代表EBNA 1的一个主要表位。267/294（90.8%）的NPC患者有针对p107的IgA抗体，但在正常个体中，只有41/577（7.1%）有IgA/p107。在其他癌症患者的血清中，11/77（14.3%）有IgA/p107反应性。还通过ELISA检测了124份IgA/VCA阳性和86份IgA/VCA阴性的NPC血清与IgA/p107的结合情况。大多数IgA/VCA阳性血清（117份）也含有IgA/p107抗体。有趣的是，在IgA/VCA阴性组中检测到74/86份有IgA/p107反应性的血清。结果表明，IgA/p107 ELISA可能成为一种有用的、用于补充IgA/VCA免疫荧光试验以检测NPC的筛查方法。
